Presenters: Paul Snyder, MA, LADC-S, CPC-I and Denis G. Patterson, DO
Online CME Credit
Fee: $50.00
Provides 1.00 hour(s) of CE/CME credit (Presented on August 10, 2021; Reviewed June 20, 2023; Expires October 1, 2025)
Provides CME credit towards the Nevada State Board of Medical Examiners' requirement for 2 hours of training related to the misuse and abuse of controlled substances, the prescribing of opioids, or addiction during each licensure period.
This webinar is part of a seven-part series going over opioid treatment, documentation methods, and patient cases.
Following participation in this course, participants should be able to:
Instructions for receiving CME/CE credit:
For questions concerning the online evaluation or your certificate, please contact our office at (775) 784-4791 or email us at cme@med.unr.edu.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Nevada Rural Health Partners (NRHP). The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 1.00 hour(s) of nursing continuing education credit.
This program provides 1.00 CME credit(s) toward the Nevada State Board of Medical Examiners' requirement for 2 hours of training related to the misuse and abuse of controlled substances, the prescribing of opioids, or addiction during each licensure period.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
The following presenters have disclosed the following relationship with a commercial interest.
Denis Patterson (presenter):
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that they do not have financial relationships with ineligible companies related to the content of this activity.
[1]. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER Online Database, released January, 2020
[2]. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER Online Database, released January, 2020
[3]. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER Online Database, released January, 2020
[4]. Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2017 on CDC WONDER Online Database, released January, 2020
[5]Volpe DA, Tobin GAM, Mellon RD, et al. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol.2011;59(3):385-390. doi:10.1016/j.yrtph.2010.12.007
[6]http://www.deadiversion.usdoj.gov/drug_chem_info/acetylfentanyl.pdf
[7] http://www.Justthinktwice.gov/five quick facts:Carfentanil; Drug Enforcement Agency (DEA)
[8] American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM- 5) (5th ed.). Arlington, VA: American Psychiatric Publishing.
[9]Nestler, E. J. (2005). Is there a common molecular pathway for addiction? Nature Neuroscience, 8(11), 1445-1449.
[10] NIDA, July (2020). Drugs, Brains, and Behavior: The Science of Addiction Drugs and the Brain
[11] Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999-2018. NCHS data brief, no 356. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020
[12] O'Donnell J, Gladden RM, Goldberger BA, Mattson CL, Kariisa M. Notes from the field: opioid-involved overdose deaths with fentanyl or fentanyl analogs detected-United States, July 2016-December 2018. MMWR Morb Mortal Wkly Rep 2020;69:271-3
[13]. Meier B. Pain Killer Emmaus, PA: Rodale Press; 2003:99 [Google Scholar]
[14]. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980;302:123. [PubMed] [Google Scholar]
[15]. Perry S, Heidrich G. Management of pain during debridement: a survey of US burn units. Pain1982;13:267-280 [PubMed] [Google Scholar]
[1]. Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. 2011.
[2]. Rich SJ. Adv Stud Pharm. 2009;6(4):115-119.
[3]. Manchikanti L, et al. Pain Physician. 2009;12:699-802.
[4]. Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. 2011.
[5]. Wang Y, et al. Obesity 2008;16(10):2323-2330.
[6]. National Vital Statistics multiple causes of death data set and Drug Enforcement Agency ARCOS System.
[7]. Davies HTO, et al. J R Soc Med. 1994;87(7):382-385.
[8]. Dworkin RH, et al. Mayo Clin Proc. 2010;85(3 suppl): S3-S14.
[9]. Schulte E, et al. Eur J Pain. 2010;14(3):308.e1-308.e10.
[10]. Breivik H, et al. Eur J Pain. 2006;10(4):287-333.
[11]. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 07;10:357-366.
[12]. Pain Research & Management. 1996;1(3):155-162
[13]. Miles Belgrade, Fairview Pain & Palliative Care Center © 2005.
[14]. Bruce D. Naliboff, Ph.D. with support from VA Health Services Research and Development. Wu SM, Compton P, Bolus R, et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage. 2006;32(4):342-351.
[15]. Abuse, National Institute on Drug. "NIDAMED: Clinical Resources | National Institute on Drug Abuse (NIDA)." National Institute on Drug Abuse, National Institute on Drug Abuse, http://www.drugabuse.gov/nidamed-medical-health-professionals. Accessed 26 Jan. 2021.
[16]. Atluri, Sairam. "Development of a Screening Tool to Detect the Risk of Inappropriate Prescription Opioid Use in Patients with Chronic Pain ." Pain Physician , 2004.
[17]. Dowell, Deborah, et al. "CDC Guideline for Prescribing Opioids for Chronic Pain-United States, 2016." JAMA, no. 15, American Medical Association (AMA), Apr. 2016, p. 1624. Crossref, doi:10.1001/jama.2016.1464.
[18]. Holmes, Cara P., et al. "An Opioid Screening Instrument: Long-Term Evaluation of the Utility of the Pain Medication Questionnaire." Pain Practice, no. 2, Wiley, May 2006, pp. 74-88. Crossref, doi:10.1111/j.1533-2500.2006.00067.x.
[19]. "PainEDU | Inflexxion | Pain Education for Clinicians." PainEDU, http://painedu.org. Accessed 26 Jan. 2021.